Yoshikatsu Koga

National Cancer Center Hospital East — Japan

Medicine · Health Sciences

25h-index2.2kcitations143works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(34), HER2/EGFR in Cancer Research(33), Cancer Genomics and Diagnostics(16), Nanoparticle-Based Drug Delivery(15), Radiopharmaceutical Chemistry and Applications(13)

Publications143 total

Attenuated Toxicity and Antitoxic Mechanism via Sodium Iodide Symporter Inhibition-Based Tumor-Selective Delivery in Astatine-211 Radioimmunotherapy
Molecular Pharmaceutics·2026Open Access
Near‐Infrared Photoimmunotherapy Targeting Esophagogastric Junction Adenocarcinoma With Fully Human Anti‐ <scp>EpCAM</scp> Antibody
Cancer Science·2025Open Access
DDS Research in the Post-Animal Era
Drug Delivery System·2025Open Access
Ultra-sensitive pan-cancer molecular residual disease assessment using whole-genome sequencing-based personalized ctDNA panel: Initial results from the MONSTAR-SCREEN-3 project.
Journal of Clinical Oncology·2025· 3 cited
SCRUM-Japan MONSTAR-SCREEN-3: Comprehensive tumor microenvironment analysis via multi-omics in a large-scale prospective study.
Journal of Clinical Oncology·2025
Abstract 1154: SCRUM-Japan MONSTAR-SCREEN-3: A large-scale multi-institutional prospective study platform integrating spatial transcriptomics and multi-omics analysis for comprehensive understanding of tumor microenvironment dynamics
Cancer Research·2025
Abstract 4344: Broader therapeutic window via combining sodium ascorbate for protecting radioactive antibodies from radiolysis and sodium perchlorate for blocking sodium iodide symporter in radioimmunotherapy with astatine-211
Cancer Research·2025
Abstract 3504: Evaluation of T cell-engaging bispecific antibody using perfusable three-dimensional model
Cancer Research·2025
New year greetings from editors of Drug Delivery System
Drug Delivery System·2025Open Access
Supplementary Table 2 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine
2024Open Access
Supplementary Figure 2 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine
2024Open Access
Supplementary Table 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine
2024Open Access
Supplementary Figure 4 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine
2024Open Access
Data from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine
2024Open Access
Supplementary Table 4 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine
2024Open Access
Supplementary Figure 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine
2024Open Access
Supplementary Table 3 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine
2024Open Access
Supplementary Figure 3 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine
2024Open Access
Possibility of determining high quantitative fecal occult blood on stool surface using hyperspectral imaging
Journal of Gastroenterology·2024· 2 citedOpen Access
Anti‐tissue factor antibody conjugated with monomethyl auristatin E or deruxtecan in pancreatic cancer models
Cancer Science·2024· 6 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Yasuhiro Matsumura(40), Masahiro Yasunaga(38), Ryo Tsumura(16), Hiroki Takashima(10), Shino Manabe(9), Yoshiyuki Yamamoto(8), Jun‐ichiro Kuroda(6), Ryuta Sato(6), Jun-ichiro Kuroda(6), Amane Takahashi(5), Seiichiro Yamamoto(5), Mitsunori Harada(5), Nobuyoshi Yamazaki(5), Hirotsugu Kenmotsu(5), Takahiro Anzai(5), Yoshihiro Moriya(4), Takayuki Akasu(4), Shin Fujita(4), Ichinosuke Hyodo(4), Toshihiko Doi(4)